Zofran Lawsuit Plaintiffs Allege GSK Concealed Birth Defect Risks

November 23, 2015 – – ZofranLegal.com reports on allegations among Zofran birth defect lawsuit plaintiffs which allege that manufacturer GlaxoSmithKline intentionally hid their drug’s link to birth defects. In a recent complaint filed in the U.S. District Court for the Western District of Louisiana, two more plaintiffs have alleged that their use of anti-nausea medication Zofran while pregnant caused their children to be born with serious birth defects. In this case, the defects noted include accelerated ventricular arrhythmia, intermittent tachypnea, perimembranous ventricular septal defects, and atrial septal defect.

These plaintiffs are not alone in their complaints. Across the nation, many families have stepped forward connecting their baby’s exposure to Zofran while in utero to birth defects. The defects most commonly noted are cleft lip and palate, ventricular septal defect and atrial septal defect, transposition of the greater vessels, tetralogy of fallot, clubfoot, and kidney defects. The women are prescribed the drug to combat nausea associated with morning sickness. This most commonly occurs during the first trimester, which is also a time when the fetus does much of its heart, mouth, and limb tissue development.

Despite the fact that the drug is prescribed to an estimated 1 million women nationwide each year, the U.S. Food and Drug Association never approved Zofran for this use. More importantly, perhaps, it was never tested for safety for use on pregnant mothers and their developing babies, either. The drug was approved by the FDA in 1991 specifically to treat cancer patients who had undergone chemotherapy or radiation therapy, or to treat patients who had undergone anesthesia for a surgical procedure.

In this particular lawsuit, the two plaintiffs are suing pharmaceutical giant GlaxoSmithKline accusing them of promoting their anti-nausea drug in this “off-label” fashion and concealing apparent risks that its use by expectant mothers could cause severe birth defects to develop in unborn babies.

Details within their complaint allege: “By 2000, GSK had received at least 32 reports of birth defects of congenital heart disease, dysmorphism, intrauterine death, stillbirth, kidney malformation, congenital diaphragmatic anomaly, congenital musculoskeletal anomalies, and orofacial anomalies, among others.” The women allege that despite being aware of this information, GSK continued to market the drug without any warnings relating to birth defects.

As additional lawsuits like these continue to crop up against Zofran and GSK, the attorneys at Monheit Law are working to ensure that everyone involved has the right to look into their legal options. Anyone who was prescribed Zofran while pregnant and who subsequently gave birth to a baby with defects may be entitled to compensation. These individuals are currently offered free legal consultations by Monheit Law.

To obtain additional information concerning Zofran lawsuits, or to ask questions, please call Attorney Michael Monheit, Esq. at (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60005712